Press Release - September 6, 2018

Journal Cell Features New Immunohistochemistry Imaging Technology from IONpath that Images 40+ Proteins
on a Single Slide

Paper describes the only multiplexed mass spectrometry imaging technology with unrivaled sensitivity, throughput, and resolution.

Menlo Park, California, Sept. , 2018 - IONpath, a venture-backed commercial-stage pathology startup, today announced that a paper detailing the performance of its new Multiplexed Ion Beam Imaging (MIBI ) technology was accepted by the journal Cell and will be featured in the September 6 issue. This study will also be shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018. The study leveraged IONpath’s MIBIscope instrument to define tumor and immune cell spatial compositions leading to a discovery of a cell signature that predicts therapeutic response for triple-negative breast cancer...

“The work by Keren et al highlights the value of characterizing the intact tumor microenvironment with a comprehensive antibody panel and defining meaningful spatial relationships between tumor and infiltrating immune cells. The approach, MIBI-TOF, will be invaluable for analyzing potential mechanisms of immune evasion and responses to immunotherapy in multiple cancers”, said Dr. Margaret Shipp, Professor of Medicine and Director Lymphoma Program, Dana-Farber Cancer Institute.

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging

Keren et al. Cell, September 2018

cell publication image.jpg
image webinar website.jpg

Webinar Cell Publication 
Comprehensive Enumeration of Immune Cells in Solid Tumors

October 2nd, 2018 - 9 AM PST/12 PM ET

Presented by Michael Angelo, MD, PhD
Assistant Professor of Pathology. Stanford Medicine, Dept. of Pathology

Learning Objectives

  • Learn how the structure of the immune infiltrate is deterministic of survival in TNBC. 
  • Learn how MIBI technology enables simultaneous imaging of 40+ markers in FFPE tissue.

Visualize Cell Publication Data with MIBItracker Software

Different analysis modes let you customize the display for each image or image set including
selecting channels for overlay, setting channel relative intensity, pixel smoothing, and channel pseudo-color. 

MIBItracker is accessible on any web browser and two data sets are available for review.

IONpath Brochure picture with border.jpg

MIBIscope I System

The MIBIscope I system lets pathologists and scientists gain new insights in the understanding of tissue microenvironment complexities with unmatched multiplexed image quality.

•    Visualize 40+ markers simultaneously
•    Image at the sub-cellular resolution
•    Detect low abundance proteins
•    Rescan slides at multiple resolutions


Image 40+ markers simultaneously at resolution superior to light microscopy.


Analyze any tissue or sample type, whether fresh, frozen or FFPE.


Single antibody sensitivity and no background staining lets you visualize low abundance targets.



Simultaneously identify all major classes of tumor-infiltrating lymphocytes to assess response to immuno-oncology interventions.


Analyze co-expression of dozens of proteins in brain biopsies with no background.

Clinical Trials

Identify biomarkers to guide treatment selection or demonstrate drug efficacy.